DaVita Inc.’s Stock Price Stumbles to $150.92, Recording a 1.51% Dip: A Crucial Market Update

DaVita Inc. (DVA)

150.92 USD -2.32 (-1.51%) Volume: 1.09M

DaVita Inc.’s stock price stands at 150.92 USD, experiencing a -1.51% change this trading session with a trading volume of 1.09M. The healthcare company has notably grown with a year-to-date percentage change of +44.06%, demonstrating a robust stock market performance.

Latest developments on DaVita Inc.

DaVita HealthCare (DVA) has been making headlines recently with key insider stock movements. Javier Rodriguez, the CEO, and the CFO have both sold significant amounts of company stock, with Rodriguez cashing out $6.26 million and the CFO selling over $10 million worth. Despite this, Kintegral Advisory LLC has purchased shares of DaVita, showing confidence in the company. The Zacks Analyst Blog has also highlighted DaVita, indicating positive momentum. On the other hand, the State of Michigan Retirement System has trimmed its stock holdings in DaVita. With mixed signals from insiders and investors, the stock price of DaVita is experiencing fluctuations, making it a great momentum stock to watch closely for potential buying opportunities.

A look at DaVita Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, DaVita has a mixed long-term outlook. While the company scores high in Growth and Momentum, indicating potential for future expansion and positive stock performance, it lags behind in Value, Dividend, and Resilience scores. This suggests that although DaVita may experience growth and momentum in the future, investors should be cautious due to lower scores in other key areas.

DaVita Inc. is a healthcare company that specializes in providing kidney dialysis services for patients with chronic kidney failure. With a global presence, DaVita serves patients worldwide, offering a variety of healthcare services. Despite its strong performance in Growth and Momentum according to Smartkarma Smart Scores, investors should consider the company’s overall outlook carefully, taking into account its lower scores in Value, Dividend, and Resilience.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma